Second Orthopedic and Traumatology Clinic, University of Pisa, Pisa, Italy.
Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
BMC Musculoskelet Disord. 2023 Mar 11;24(1):184. doi: 10.1186/s12891-023-06278-0.
BACKGROUND: Delayed bone healing and nonunions represent a great challenge for the orthopedic surgeon. In addition to traditional surgical approaches, increasing attention is being given to the use of systemic anabolic therapy with Teriparatide, whose efficacy in preventing osteoporotic fractures is widely validated and whose application as a promoter of bone healing has been described but it is still debated. The aim of the study was to evaluate bone healing in a series of patients with delayed unions or nonunions treated with Teriparatide in conjunction with eventual appropriate surgical procedure. METHODS: Twenty patients with an unconsolidated fracture that were treated at our Institutions from 2011 to 2020 with Teriparatide were retrospectively included into the study. The pharmacological anabolic support was used off-label with a planned duration of 6 months; radiographic healing was evaluated at 1-, 3- and 6-months follow-up outpatient visits over plain radiographs. Also, eventual side-effects were registered. RESULTS: Radiographic signs indicative of favorable evolution of the bone callus were observed as early as at 1 month of therapy in 15% of cases; at 3 months, healing progression was appreciated in 80% of cases and complete healing in 10%; at 6 months, 85% of delayed and nonunions had healed. In all patients, the anabolic therapy was well tolerated. CONCLUSIONS: In accordance to Literature, this study suggests that Teriparatide plays a potentially important role in the treatment of some forms of delayed unions or nou-nions, even in the presence of failure of hardware. The results suggest a greater effect of the drug when associated with a condition in which the bone is in an active phase of callogenesis, or with a "revitalizing" treatment which represents a local (mechanical and/or biological) stimulus to the healing process. Despite the small sample size and the variety of cases, the efficacy of Teriparatide in treating delayed unions or nonunions emerged, highlighting how this anabolic therapy can represent a useful pharmacological support in the treatment of such a pathology. Although the results obtained are encouraging, further studies, particularly prospective and randomized, are needed to confirm the efficacy of the drug, and define a specific treatment algorithm.
背景:延迟愈合和骨不连是骨科医生面临的巨大挑战。除了传统的手术方法外,人们越来越关注使用特立帕肽进行全身合成代谢治疗,其预防骨质疏松性骨折的疗效已得到广泛验证,其促进骨愈合的应用也已得到描述,但仍存在争议。本研究旨在评估特立帕肽联合适当手术治疗延迟愈合或骨不连患者的骨愈合情况。
方法:回顾性纳入 2011 年至 2020 年在我院接受特立帕肽治疗的未愈合骨折患者 20 例。骨代谢促进治疗为超说明书应用,预计疗程为 6 个月。通过门诊随访,于治疗后 1、3 和 6 个月行平片检查评估骨愈合情况,并记录可能出现的不良反应。
结果:15%的病例在治疗后 1 个月即可观察到骨痂有良好的愈合迹象;3 个月时,80%的病例骨愈合进展,10%的病例完全愈合;6 个月时,85%的延迟愈合和骨不连病例已愈合。所有患者均能耐受合成代谢治疗。
结论:本研究结果与文献一致,提示特立帕肽在治疗某些类型的延迟愈合或骨不连中可能具有重要作用,即使内固定失败也是如此。研究结果表明,当特立帕肽与骨处于活跃的骨生成阶段的情况相关,或与“复苏”治疗相关时,该药物的效果更为显著,“复苏”治疗代表了对愈合过程的局部(机械和/或生物)刺激。尽管样本量较小且病例多样,但特立帕肽治疗延迟愈合或骨不连的疗效仍然显著,这突出表明这种合成代谢治疗可作为治疗此类疾病的有用药物支持。虽然研究结果令人鼓舞,但仍需要进一步的研究,特别是前瞻性和随机研究,以确认该药物的疗效,并制定特定的治疗方案。
BMC Musculoskelet Disord. 2023-3-11
Injury. 2016-1
Clin Orthop Relat Res. 2016-5
Clin Pract. 2021-1-29
Arq Bras Endocrinol Metabol. 2013-3
Eur J Orthop Surg Traumatol. 2013-11
J Hand Surg Glob Online. 2025-8-13
Bioengineering (Basel). 2024-5-22
Ther Adv Musculoskelet Dis. 2023-7-29
Eur Rev Med Pharmacol Sci. 2022-11
Bioengineering (Basel). 2022-10-16
Front Endocrinol (Lausanne). 2022
Int J Environ Res Public Health. 2022-6-15
J Biol Regul Homeost Agents. 2020
Clin Pract. 2021-1-29
J Bone Metab. 2020-8
Handb Exp Pharmacol. 2020